BIT 5.26% 2.0¢ biotron limited

same old just another day

  1. 2,892 Posts.
    lightbulb Created with Sketch. 306
    BIT225 reduces the intracellular HIV-1 burden within monocyte derived dendritic cells resulting in reduced transfer of virus to more permissive CD4+ T-cells

    J. Wilkinson1, G. Ewart2, C. Luscombe2, M. Miller2

    Background:
    Dendritic cells (DC) are able to bind, uptake and disseminate HIV-1
    during the very early stages of infection. HIV-1 exposed DC rapidly mature and migrate from the site of
    infection to the lymph nodes (~24h) where they present HIV-1 to CD4+
    T cells, resulting in explosive viral replication within the host. Our lead compound, BIT225 blocks Vpu
    ion channel activity and demonstrates strong anti-HIV-1 activity in human
    macrophages. Here we further
    define the extent of BIT225 antiviral activity in relation to HIV-1BaL
    infected monocyte-derived DC (MDDC).


    Methods: Day 6
    MDDC were infected with HIV-1BaL at MOI of 0.05 and cultured alone and
    with uninfected, PHA-activated, heterologous CD4+ T cells at
    specific time points (0-168h) and co-cultured for an additional 7 days ±BIT225.
    HIV-1 was quantified in the MDDC cultures and MDDC-CD4+
    co-cultures with the difference an estimate of HIV-1 transfer.


    Results: BIT225
    treatment post-infection resulted in a lower virus burden within the infected
    MDDC as measured by reduced virus transfer in trans (< 24 h) and additionally a reduced transfer of de
    novo virus in cis compared to DMSO treated controls. This effect was dose dependent, with
    BIT225 at the highest dose of 20 uM resulting in 80% less transfer of virus in trans and >90% inhibition during the cis phase of transfer.


    Conclusions: BIT225
    resulted in reduced transfer of HIV-1 to activated T cells in both trans and cis
    with no cellular toxicity. BIT225
    may induce a more hostile environment within the intracellular compartments
    facilitating increased endolysosomal degradation or viral assembly as we have
    previously reported in BIT225 treated macrophages. We are currently attempting to confirm this possibility
    using electron and confocal microscopy.
    Therapies able to limit the dissemination of HIV-1 by DC to more
    permissive host cells at very early stages of infection could be of great
    clinical value.




    AIDS 2010 - XVIII International AIDS Conference
    Abstract no. TUPDA103

    Suggested Citation
    "J.Wilkinson, et al. BIT225 reduces the intracellular HIV-1 burden within monocyte derived dendritic cells resulting in reduced transfer of virus to more permissive CD4+ T-cells. : AIDS 2010 - XVIII International AIDS Conference: Abstract no. TUPDA103
 
watchlist Created with Sketch. Add BIT (ASX) to my watchlist
(20min delay)
Last
2.0¢
Change
0.001(5.26%)
Mkt cap ! $18.04M
Open High Low Value Volume
2.0¢ 2.1¢ 2.0¢ $9.288K 460.4K

Buyers (Bids)

No. Vol. Price($)
1 15038 2.0¢
 

Sellers (Offers)

Price($) Vol. No.
2.1¢ 24000 1
View Market Depth
Last trade - 15.05pm 07/11/2024 (20 minute delay) ?
BIT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.